Bromo-DragonFLY

Bromo-DragonFLY, also known as DOB-DragonFLY (DOB-DFLY), is a psychedelic drug of the phenethylamine, DOx, and FLY families. It is taken orally. The drug has a delayed onset of up to 6 hours and a very long duration of up to 1 to 3 days. Side effects of Bromo-DragonFLY include nausea and vomiting, headache, tachycardia, hypertension, anxiety, panic attacks, pupil dilation, convulsions and vasoconstriction, among others. The drug acts as an agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It is also a potent monoamine oxidase A (MAO-A) inhibitor. Bromo-DragonFLY was first described in the scientific literature by David E. Nichols and colleagues in 1998. It was encountered as a novel designer drug in 2006. The drug has been associated with an unusually high degree of toxicity and numerous hospitalizations and fatalities. It has become a controlled substance in various countries in the world.